Characteristic | Value |
---|---|
Age at diagnosis – median (range) | 66.8 (55.0–85.1) |
Male – n (%) | 7 (58.3) |
Laterality – n (%) | |
 Left Kidney | 4 (33.3) |
 Right Kidney | 8 (66.7) |
Histology – n (%) | |
 Clear Cell | 9 (75) |
 Papillary | 2 (16.7) |
 Othera | 1 (8.3) |
Location of Metastasesb | |
 Lung | 10 (83.3) |
 Bone | 6 (50) |
 Lymph nodes | 5 (41.7) |
 Brain | 3 (25) |
 Otherc | 4 (33.3) |
Karnofsky Performance Status – median (range) | 70 (40–90) |
Karnofsky Performance Status – n (%) | |
 ≥ 80% | 5 (41.7) |
 <  80% | 7 (58.3) |
IMDC Prognostic Group – n (%) | |
 Favorable | 1 (8.3) |
 Intermediate | 8 (66.7) |
 Poor | 3 (25) |
Systemic Therapy Timingb – n (%) |  |
 None | 6 (50) |
 Pre-SABR | 1 (8.3) |
 Post-SABR | 4 (33.3) |
 Both | 1 (8.3) |
Systemic Therapy Type – n (%) | |
 None | 6 (50) |
 Pazopanib or Sunitinib | 5 (41.7) |
 Temsirolimus or Everolimus | 2 (16.7) |
SABR Treatment Technique – n (%) | |
 VMAT | 7 (58.3) |
 TOMO | 5 (41.7) |
Dose Cohort (Gy) – n (%) | |
 25/5 | 3 (25) |
 30/5 | 6 (50) |
 35/5 | 3 (25) |
Primary tumor sized (cm) – median (range) | 8.7 (4.8–13.8) |
Actuarial median follow-up (months)e - median (95% CI) | 22 (4.63, N/A) |